pCPA Activity Overview
Status | Total Negotiations | Summary |
---|---|---|
Active Negotiations | 44 | Non-oncology: 29 Oncology: 15 |
Under Consideration for Negotiation | 12 | Non-oncology: 8 Oncology: 4 |
Completed Negotiations | 787 | With Letter of Intent: 680 Without agreement: 107 |
Negotiations That Were Not Pursued | 108 |
pCPA activity in the last four weeks
Activity for the last four weeks. Please note that these updates may take one to two weeks to be processed.
Engagement letters issued in the last four weeks
Brand Name | Manufacturer | Indication | Engagement Date |
---|---|---|---|
Ebglyss | Eli Lilly Canada Inc. | Atopic dermatitis | |
Zilbrysq | UCB Canada Inc. | Generalized myasthenia gravis (gMG) | |
Leqvio | Novartis Pharmaceuticals Canada Inc. | Primary hypercholesterolemia (non-familial and heterozygous familial) | |
Winrevair | Merck Canada Inc. | Pulmonary Arterial Hypertension (WHO group 1) | |
Leqvio | Novartis Pharmaceuticals Canada Inc. | Primary hypercholesterolemia | |
Vyloy | Astellas Pharma Inc. | In combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal |